Strongbridge Biopharma plc
|Type||Public limited company|
|Traded as||NASDAQ: SBBP|
|Headquarters||Trevose, PA (US Location)|
|Key people||Matthew Pauls (President & CEO)|
Fredric Cohen, MD (CMO)
Strongbridge Biopharma plc (NASDAQ: SBBP) is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. The company is called Strongbridge for a reason. The name reflects the collective strength of its rare disease expertise, product portfolio and pipeline, and patient-driven culture—one that is fueled by performance, precision and heart. Strongbridge is working to remove the barriers and isolation associated with rare neuromuscular and endocrine diseases in order to connect patients with the life-enhancing treatment options they deserve. Strongbridge is registered in Ireland, and its U.S. headquarters are located just outside of Philadelphia, PA. Strongbridge Biopharma is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP. Focus. Commitment. Passion. That’s Strongbridge.
Company history[change | change source]
Founded in 1996 in Sweden as Cortendo AB, the original focus was on regulating cortisol secretion in patients with diabetes. In the course of reinventing, refocusing, and reinvigorating the company, Strongbridge Biopharma has reached a series of pivotal business and clinical milestones. In 2017, Strongbridge was awarded the PM360 Trailblazer Awards Specialty Pharma Company of the Year.